Bayer terminated a two-year-old partnership with Atara Biotherapeutics that included the development of off-the-shelf T-cell immunotherapy for high mesothelin-expressing tumors.
Researchers at Yale University published research in Molecular Biology and Evolution describing a new molecular analysis approach to quantify DNA changes that contribute to cancer growth.
BridgeBio announced that the Palo Alto, Calif.-based biopharmaceutical company signed an exclusive deal with Bristol Myers Squibb to develop and commercialize a potential treatment for cancer.
Twist Bioscience and Astellas have entered into a research collaboration and exclusive option license agreement to identify potential therapeutic antibodies which would help to reduce tumor microenvironment-mediated immunosuppression.
BioNTech continues to build on the success of the company’s mRNA COVID-19 vaccine co-developed with Pfizer, rapidly expanding its investigational pipeline to include additional infectious diseases and oncology with a first-in-class CAR-T program in solid tumors.
China-based Hutchmed failed to get the U.S. Food and Drug Administration’s approval for the company’s proposed drug for pancreatic cancer.
U.S. FDA declines to approve two more China-tested drugs
Business, China, Complete Response Letter, FDA, FDA Statements, Gastroenteropancreatic neuroendocrine tumors, Gastroenteropancreatic Neuroendocrine Tumors, Gastrointestinal Tumors, Lung Neuroendocrine Tumors, Nasopharyngeal Carcinoma (NPC), Neuroendocrine Tumors, Oncology, R&D, Shares, Therapeutics, Throat CancerThe U.S. Food & Drug Administration declined to approve two China-tested cancer treatments on Monday, saying one of the companies – Hutchmed Ltd. – needs to test its drug for the U.S. population in a diverse multi-regional trial.
AACR: Monday’s Stars Include Affimed, Hoth and Blueprint
American Association for Cancer Research (AACR), Antibodies, Checkpoint Inhibitors, Clinical Trials, DNA, Efficacy Data, Epidermal Growth Factor Receptor-Mutated (EGFRm) Non-Small Cell Lung Cancer (NSCLC), Hodgkin Lymphoma, Microsatellite instability-high (MSI-H) cancer, Non-Hodgkin Lymphoma, PD-1/PD-L1 inhibitors, R&D, Solid Tumors, TherapeuticsThe American Association for Cancer Research (AACR) Annual Meeting is running from April 7-13 in New Orleans, with hundreds of presentations on cutting-edge cancer research. The presentations run the gamut from preclinical studies to late-stage clinical trials. BioSpace looks at some of the preclinical and early-stage studies presented.
At the Clinical Trials Plenary Session at the 2022 AACR Annual Meeting, Dr. John Haanen, M.D., Ph.D., of the Netherlands Cancer Institute presented data from BioNTech’s ongoing first-in-human Phase I/II trial of the company’s CAR-T cell therapy BNT211 in patients with advanced solid tumors.
Roche partnered with Bristol Myers Squibb to utilize two digital pathology platforms that would advance research into treatment options for patients diagnosed to have solid tumors.